Biblio Discovery — Demo Discovery Service

12 results for "Barczyk, Adam"

Showing 1–12 · 0.77 seconds · RSS

  1. Journal Article Full text

    Advances in Respiratory Medicine (ARM)—Past, Present, Future

    Barczyk, Adam

    Adv Respir Med · 2022 · English · PubMed Central

  2. Journal Article Full text

    Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study

    Rzepka-Wrona, Patrycja; Skoczyński, Szymon; Barczyk, Adam

    Int J Mol Sci · 2022 · English · PubMed Central

    In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial pneumonia with autoimmune features (IPAF), connective-tissue-disease-associated interstitial lung diseases (CTD-ILDs), and idiopathic interstitial pneumonias (IIPs). Forty participants were recruited…

  3. Journal Article Full text

    Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF): Protocol for a Multicenter Prospective Study

    Rzepka-Wrona, Patrycja; Skoczyński, Szymon; Piotrowski, Wojciech J et al.

    JMIR Res Protoc · 2023 · English · PubMed Central

    BACKGROUND: “Interstitial lung disease” (ILD) is a broad term encompassing diseases of different backgrounds. “Interstitial pneumonia with autoimmune features” (IPAF) is a recent term that implies the presence of autoimmunity. OBJECTIVE: This study aims to determine the characteristics of Polish…

  4. Journal Article Full text

    Recommendations Following Hospitalization for Acute Exacerbation of COPD—A Consensus Statement of the Polish Respiratory Society

    Białas, Adam Jerzy; Barczyk, Adam; Damps-Konstańska, Iwona et al.

    Adv Respir Med · 2026 · English · PubMed Central

    HIGHLIGHTS: What are the main findings? A multidisciplinary team should be involved in developing discharge instructions after hospitalization for a chronic obstructive pulmonary disease (COPD) exacerbation to ensure clear, consistent, and comprehensive documentation. Discharge instructions should…

  5. Journal Article Full text

    2024 Update on Position Statement by Experts from the Polish Society of Allergology and the Polish Respiratory Society on the Evaluation of Efficacy and Effectiveness of Single Inhaler Triple Therapies in Asthma Treatment

    Śliwiński, Paweł; Antczak, Adam; Barczyk, Adam et al.

    Adv Respir Med · 2024 · English · PubMed Central

    HIGHLIGHTS: What are the main findings? Inhaled triple-combination medications, ICS/LABA/LAMA, within a singular inhalation device yield a dual benefit of minimizing the likelihood of adverse effects linked with the principal therapeutic agent for asthma management, namely ICS, while concurrently…

  6. Journal Article Full text

    Mallampati Score Is an Independent Predictor of Active Oxygen Therapy in Patients with COVID-19

    Dyrbuś, Maciej; Oraczewska, Aleksandra; Szmigiel, Szymon et al.

    J Clin Med · 2022 · English · PubMed Central

    Mallampati score has been identified and accepted worldwide as an independent predictor of difficult intubation and obstructive sleep apnea. We aimed to determine whether Mallampati score assessed on the first patient medical assessment allowed us to stratify the risk of worsening of conditions in…

  7. Journal Article Full text

    Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study

    Barczyk, Adam; Czajkowska-Malinowska, Małgorzata; Farnik, Małgorzata et al.

    Respir Med · 2023 · English · PubMed Central

    BACKGROUND: Amantadine has been proposed as a treatment for COVID-19 because it shows anti-SARS-CoV-2 activity in vitro. However, to date, no controlled study has assessed the safety and efficacy of amantadine in COVID-19. RESEARCH QUESTION: Whether amantadine is effective and safe among patients…

  8. Journal Article Full text

    Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland

    Górska, Katarzyna; Maskey-Warzęchowska, Marta; Barnaś, Małgorzata et al.

    Ther Adv Chronic Dis · 2022 · English · PubMed Central

    BACKGROUND: Pirfenidone and nintedanib are considered as the standard of care in idiopathic pulmonary fibrosis (IPF), but there is no consensus as to which of these two agents should be regarded as first-line treatment. OBJECTIVE: To provide real-world data on therapeutic decisions of pulmonary…

  9. Journal Article Full text

    Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis

    Piotrowski, Wojciech J.; Martusewicz-Boros, Magdalena M.; Białas, Adam J. et al.

    Adv Respir Med · 2022 · English · PubMed Central

    HIGHLIGHTS: The working group of the Polish Respiratory Society (PTChP) developed guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary team should be involved in the diagnosis and treatment of progressive pulmonary fibrosis. Nintedanib alone or in…

  10. Journal Article Full text

    A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study

    Majewski, Sebastian; Białas, Adam J.; Barczyk, Adam et al.

    J Clin Med · 2023 · English · PubMed Central

    Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and efficacy profiles of nintedanib in a large real-world cohort of Polish patients with IPF. This was a…

  11. Journal Article Full text

    Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO(2) Requirements

    Neuenschwander, Fernando Carvalho; Barnett-Griness, Ofra; Piconi, Stefania et al.

    Microorganisms · 2024 · English · PubMed Central

    Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral treatment under investigation being evaluated for treatment of hospitalized patients with severe COVID-19 pneumonia. A randomized, placebo-controlled, double-blind…